2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalence
2016
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics
Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect acting antiviralsOpioid use disorderDrug interactionsUse disordersHCV direct acting antiviralsNovel direct acting antiviralsHepatitis C virus infectionHepatitis C therapeuticsHigh HCV prevalenceC virus infectionMedication-assisted therapyPharmacodynamic drug interactionsSpecific drug combinationsDrug package insertsHCV prevalenceHCV infectionHCV treatmentOpioid withdrawalActing antiviralsCombination regimenPharmacodynamic assessmentConcurrent administrationDrug levelsHigh prevalenceVirus infection
2008
Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa
Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, Pillay M, Friedland G, Sturm AW, Collaboration O. Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa. The Journal Of Infectious Diseases 2008, 198: 1582-1589. PMID: 18847372, DOI: 10.1086/592991.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisXDR tuberculosisExogenous reinfectionHuman immunodeficiency virus (HIV) infectionEffective infection control strategiesInitial isolatesCause of MDRTB treatment programsTransmission of MDRCulture-positive tuberculosisHIV infection statusImmunodeficiency virus infectionInfection control strategiesDevelopment of MDRResistant tuberculosisMultidrug-ResistantHigh prevalenceVirus infectionPatientsReinfectionRural South AfricaTreatment programTuberculosisInfection statusTugela Ferry
2007
Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa
Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa. The Journal Of Infectious Diseases 2007, 196: s482-s490. PMID: 18181698, DOI: 10.1086/521121.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisMDR-TBHIV epidemicXDR-TBDrug-resistant (XDR) TBMultidrug-resistant (MDR) TBMDR-TB treatment programmeTB treatment success rateHuman immunodeficiency virus (HIV) infectionAntiretroviral therapy rolloutXDR-TB epidemicImmunodeficiency virus infectionTreatment success rateDrug resistance surveillanceDrug resistance testingPublic health challengeAirborne infection controlPublic health infrastructureHIV programsMultidrug-ResistantHigh prevalenceVirus infectionInfection controlTreatment programTuberculosisAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
1989
Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus.
Schrager L, Friedland G, Maude D, Schreiber K, Adachi A, Pizzuti D, Koss L, Klein R. Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1989, 2: 570-5. PMID: 2555473.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHuman papillomavirus infectionPapillomavirus infectionImmunodeficiency virusLower genital tract neoplasiaGenital HPV infectionGenital tract neoplasiaSquamous cell abnormalitiesHPV infectionSquamous abnormalitiesHIV infectionHigh prevalenceCytological abnormalitiesNeoplastic disordersCervicovaginal smearsHigh riskCell abnormalitiesBlinded fashionInfectionWomenAbnormalitiesCellular changesFurther studiesVirusRisk